VINBLASTINE, INTERMITTENT BLEOMYCIN, AND SINGLE-DOSE CIS-DICHLORODIAMMINEPLATINUM(II) IN THE MANAGEMENT OF STAGE-III TESTICULAR CANCER

Abstract

A program for treating advanced testicular cancer with vinblastine, bleomycin and a single dose of cis-dichlorodiammineplatinum(II) was used to reduce the toxicity of a 5-day regimen while maintaining a high response rate. In 10 previously untreated and 6 previously treated patients, the complete remission rate was 25%. Toxic reactions were frequent; there was 1 drug-related death. This single-dose cis-dichlorodiammineplatinum(II) program is ineffective in the treatment of testicular cancer. Other means for reducing toxicity will have to be considered.